Neuralink, a company specializing in the development of brain-computer interfaces owned by entrepreneur Elon Musk, announced its success in closing a $650 million Series E funding round, according to an official statement published on the company's blog on Monday. A number of prominent names in the world of venture capital participated in this round, including ark Invest, Founders Fund, Sequoia Capital, and Thrive Capital, along with other investors. The round is the largest in the company's history to date, surpassing its previous Series D round during which it raised $280 million in 2023, in addition to an additional $43 million funding tranche that it later acquired in the same year.
Background
Since then, Neuralink has made remarkable progress in its technologies, starting with human clinical trials involving brain implants for five people with severe paralysis, a milestone for the company so far. In another important development, in May, Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration (FDA), a classification given to promising technologies with the aim of accelerating their development, evaluation, and approval..
Full Details
As revealed by Semafor last week, the new funding round raised Neuralink's market valuation to about $9 billion before investing (pre-money), reflecting growing investor confidence in the potential of this promising technology. Neuralink aims to revolutionize the relationship between humans and technology by developing brain implants that allow people with paralysis or neurological diseases to control electronic devices through their thoughts alone. Despite the medical and regulatory hurdles facing the industry, progress, along with increased financial support from Silicon Valley, suggests that this innovation is getting closer and closer to reality...
Key Takeaways
- A number of prominent names in the world of venture capital participated in this round, including ark Invest, Founders Fund, Sequoia Capital, and Thrive Capital, along with other investors.
- Since then, Neuralink has made remarkable progress in its technologies, starting with human clinical trials involving brain implants for five people with severe paralysis, a milestone for the company so far.
- In another important development, in May, Neuralink received a “Breakthrough Device” designation from the U.S.
- Food and Drug Administration (FDA), a classification given to promising technologies with the aim of accelerating their development, evaluation, and approval..
As technology continues to evolve rapidly in 2026, all eyes remain on the industry to see what comes next. Stay tuned for further updates as this story develops.
"AI Unbound: Shaping the Future, One Algorithm at a Time".